Pfizer acquires Baxter vaccines for $635m

Pfizer has entered into a definitive agreement to acquire two vaccines marketed by US biotechnology company Baxter International for $635 million.

Under the agreement, Pfizer will also acquire part of Baxter’s manufacturing plant in Orth, Austria.

The two vaccines are NeisVac-C, which helps protect against meningitis, and FSME-IMMUN/TicoVac, a vaccine for tick-borne encephalitis.

“Every day people of all ages benefit from safe and effective vaccines,” said Pfizer’s vaccines president Susan Silbermann.

“Through this acquisition, we will add two high-quality and life-saving vaccines that bring scale and depth to our portfolio.”

The transaction is expected to close by the end of 2014.

More on this story

Big Pharma

EC signs contract with Pfizer to access watershed vaccine

12 November 2020 The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.

Americas

Baxter sues B.Braun in revived kidney treatment patent dispute

16 November 2020 American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.